Corient Private Wealth LP Takes Position in Moderna, Inc. $MRNA

Key Points

• Corient Private Wealth LP initiated a position in Moderna during the second quarter, purchasing 65,594 shares valued at approximately $4.6 million. Institutional investors collectively own 75.33% of the company.
• Analyst sentiment remains cautious: Moderna has a consensus “Hold” rating and an average price target of $80.53, despite several firms issuing upgrades or raising targets.
• Moderna reported a quarterly loss of $1.97 per share, slightly better than estimates, while revenue reached $145 million and grew 2.1% year over year. The stock opened at $140.34 and has a 52-week range of $22.28 to $176.66.

Corient Private Wealth LP bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 65,594 shares of the company's stock, valued at approximately $4,593,000.

Several other institutional investors have also bought and sold shares of the stock. MUFG Securities EMEA plc bought a new position in Moderna during the 2nd quarter valued at $28,000. Allied Private Wealth LLC bought a new stake in shares of Moderna in the 2nd quarter worth $30,000. Canton Hathaway LLC bought a new stake in shares of Moderna in the 1st quarter worth $31,000. EverSource Wealth Advisors LLC raised its holdings in shares of Moderna by 148.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company's stock valued at $37,000 after purchasing an additional 801 shares during the last quarter. Finally, Assetmark Inc. raised its holdings in shares of Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company's stock valued at $41,000 after purchasing an additional 208 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Analysts Set New Price Targets

MRNA has been the topic of several analyst reports. Loop Capital set a $135.00 price target on shares of Moderna in a report on Wednesday, August 19th. Piper Sandler reiterated an "overweight" rating on shares of Moderna in a research note on Monday, August 3rd. CLSA raised shares of Moderna to an "outperform" rating in a research report on Friday. Bank of America raised Moderna from an "underperform" rating to a "neutral" rating in a report on Wednesday, August 19th. Finally, Citigroup increased their price target on Moderna from $41.00 to $60.00 and gave the company a "neutral" rating in a research report on Monday, August 3rd. Seven equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $80.53.

Moderna Stock Performance

NASDAQ MRNA opened at $140.34 on Tuesday. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $176.66. The company has a 50-day simple moving average of $78.73 and a 200 day simple moving average of $60.54. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The company has a market capitalization of $56.03 billion, a PE ratio of -17.56 and a beta of 0.91.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same quarter in the previous year, the firm posted ($2.13) earnings per share. The company's revenue for the quarter was up 2.1% on a year-over-year basis. On average, research analysts predict that Moderna, Inc. will post -6.11 EPS for the current year.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported encouraging results from their cancer-vaccine collaboration, supporting Moderna’s strategy to expand beyond COVID-19 vaccines into personalized oncology treatments. The results have attracted positive attention from market commentator Jim Cramer and helped drive investor enthusiasm. Jim Cramer Called Moderna Inc. and Merck’s Trial Results Encouraging
• Positive Sentiment: Recent clinical evidence has provided a major boost to the broader mRNA sector after a difficult period for the technology. Coverage highlights the potential medical and commercial significance of Moderna’s cancer-vaccine work, particularly as the company seeks to establish growth drivers beyond respiratory vaccines. After a Rough Stretch, mRNA Gets a Boost
• Positive Sentiment: Moderna received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines targeting the latest SARS-CoV-2 subvariant, as well as mFlusiva, its first mRNA influenza vaccine for adults aged 50 and older. The approvals broaden its respiratory portfolio and could improve the company’s long-term commercial opportunity in seasonal vaccines. What Do Moderna FDA Vaccine Approvals Mean for Its Respiratory Push?
• Positive Sentiment: Argus upgraded Moderna to “Buy,” adding a more bullish analyst view following the company’s clinical and regulatory developments. Argus Upgrades Moderna to Buy
• Neutral Sentiment: Trading volume increased significantly after the analyst upgrade, indicating heightened investor interest and strong momentum in MRNA shares. However, heavy activity can also reflect short-term speculation following the stock’s steep rally. Moderna Sees Large Volume Increase After Analyst Upgrade
• Negative Sentiment: Analysts overall maintain an average “Hold” rating, signaling that Wall Street remains cautious despite the recent clinical progress. The stock’s rapid appreciation has also raised concerns about valuation and the risk of profit-taking if additional trial results do not meet high expectations. Moderna Receives Average Rating of Hold

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 53,336 shares of the firm's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president directly owned 1,483,848 shares of the company's stock, valued at $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the business's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 10.80% of the company's stock.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source